Concomitantly with these main targeted therapies, there are others that have already been approved by the FDA for lung cancer treatment targeting KRAS (G12C mutation), MET (exon 14 skipping), NTRK, HER2, and RET fusion. This evidence concerns the gene RET and lung carcinoma.